Dupilumab versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison
Abstract Introduction Dupilumab and lebrikizumab have demonstrated efficacy in atopic dermatitis (AD) clinical trials; however, no direct comparisons exist. Methods Efficacy outcome achievement (dupilumab and lebrikizumab with topical corticosteroids [TCS]) at 16 weeks and efficacy outcomes maintena...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2025-07-01
|
| Series: | Dermatology and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s13555-025-01479-y |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849388155885584384 |
|---|---|
| author | Sonja Ständer Andreas Pinter Firas G. Hougeir Patricia Guyot Yingxin Xu Amy H. Praestgaard Nick Freemantle Ana B. Rossi Gaëlle Bégo-Le-Bagousse Zhixiao Wang Kerry Noonan Mike Bastian |
| author_facet | Sonja Ständer Andreas Pinter Firas G. Hougeir Patricia Guyot Yingxin Xu Amy H. Praestgaard Nick Freemantle Ana B. Rossi Gaëlle Bégo-Le-Bagousse Zhixiao Wang Kerry Noonan Mike Bastian |
| author_sort | Sonja Ständer |
| collection | DOAJ |
| description | Abstract Introduction Dupilumab and lebrikizumab have demonstrated efficacy in atopic dermatitis (AD) clinical trials; however, no direct comparisons exist. Methods Efficacy outcome achievement (dupilumab and lebrikizumab with topical corticosteroids [TCS]) at 16 weeks and efficacy outcomes maintenance (dupilumab and lebrikizumab monotherapy without TCS) at 52 weeks were assessed using a placebo-adjusted Bucher indirect treatment comparison (ITC). Week 16 data were sourced from LIBERTY AD CHRONOS (dupilumab, n = 106; placebo, n = 315) and ADhere (lebrikizumab, n = 145; placebo, n = 66) trials. Week 52 data were sourced from SOLO-CONTINUE (dupilumab, n = 80; placebo, n = 39) and ADvocate 1 and 2 (lebrikizumab, n = 231; placebo, n = 60) trials, including patients who had achieved ≥ 75% improvement from baseline in Eczema Area and Severity Index (EASI)-75 or Investigator’s Global Assessment (IGA) score 0/1 (clear/almost clear) at week 16. Results are presented as odds ratios (ORs) with 95% confidence intervals (CIs). Results At week 16, patients receiving dupilumab every 2 weeks (q2w) + TCS had a significantly higher likelihood of achieving EASI-75 (OR 2.4; 95% CI 1.1–5.1) and a ≥ 4-point improvement in Peak Pruritus Numeric Rating Scale (PP-NRS; OR 2.7; 95% CI 1.2–6.0) versus those receiving lebrikizumab q2w + TCS. ORs for other endpoints (IGA-0/1 and ≥ 4-point improvement in Dermatology Life Quality Index) numerically favored dupilumab. At week 52, dupilumab q2w maintained a significantly higher OR for EASI-75 (OR 3.5; 95% CI 1.2–10.5) versus lebrikizumab every 4 weeks. ORs for EASI-90 (OR 3.3; 95% CI 1.0–11.3), IGA 0/1 (OR 3.3; 95% CI 0.7–15.1), and PP-NRS (OR 8.8; 95% CI 0.9–84.8) numerically favored dupilumab. Conclusions Placebo-adjusted Bucher ITC analyses showed that the likelihood of achieving efficacy outcomes at 16 weeks and maintaining efficacy outcomes at 52 weeks was higher for dupilumab versus lebrikizumab recipients. Graphical Abstract |
| format | Article |
| id | doaj-art-7c1b5f6d43124470aa2dc77dd39e5fa7 |
| institution | Kabale University |
| issn | 2193-8210 2190-9172 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Adis, Springer Healthcare |
| record_format | Article |
| series | Dermatology and Therapy |
| spelling | doaj-art-7c1b5f6d43124470aa2dc77dd39e5fa72025-08-20T03:42:23ZengAdis, Springer HealthcareDermatology and Therapy2193-82102190-91722025-07-011592537255110.1007/s13555-025-01479-yDupilumab versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment ComparisonSonja Ständer0Andreas Pinter1Firas G. Hougeir2Patricia GuyotYingxin Xu3Amy H. PraestgaardNick Freemantle4Ana B. RossiGaëlle Bégo-Le-BagousseZhixiao Wang5Kerry NoonanMike BastianSection Pruritus Medicine, Department of Dermatology and Center for Chronic Pruritus, University Hospital MünsterGoethe-University Frankfurt Am MainSoutheast Research SpecialistsRegeneron Pharmaceuticals IncInstitute of Clinical Trials and Methodology, University College LondonRegeneron Pharmaceuticals IncAbstract Introduction Dupilumab and lebrikizumab have demonstrated efficacy in atopic dermatitis (AD) clinical trials; however, no direct comparisons exist. Methods Efficacy outcome achievement (dupilumab and lebrikizumab with topical corticosteroids [TCS]) at 16 weeks and efficacy outcomes maintenance (dupilumab and lebrikizumab monotherapy without TCS) at 52 weeks were assessed using a placebo-adjusted Bucher indirect treatment comparison (ITC). Week 16 data were sourced from LIBERTY AD CHRONOS (dupilumab, n = 106; placebo, n = 315) and ADhere (lebrikizumab, n = 145; placebo, n = 66) trials. Week 52 data were sourced from SOLO-CONTINUE (dupilumab, n = 80; placebo, n = 39) and ADvocate 1 and 2 (lebrikizumab, n = 231; placebo, n = 60) trials, including patients who had achieved ≥ 75% improvement from baseline in Eczema Area and Severity Index (EASI)-75 or Investigator’s Global Assessment (IGA) score 0/1 (clear/almost clear) at week 16. Results are presented as odds ratios (ORs) with 95% confidence intervals (CIs). Results At week 16, patients receiving dupilumab every 2 weeks (q2w) + TCS had a significantly higher likelihood of achieving EASI-75 (OR 2.4; 95% CI 1.1–5.1) and a ≥ 4-point improvement in Peak Pruritus Numeric Rating Scale (PP-NRS; OR 2.7; 95% CI 1.2–6.0) versus those receiving lebrikizumab q2w + TCS. ORs for other endpoints (IGA-0/1 and ≥ 4-point improvement in Dermatology Life Quality Index) numerically favored dupilumab. At week 52, dupilumab q2w maintained a significantly higher OR for EASI-75 (OR 3.5; 95% CI 1.2–10.5) versus lebrikizumab every 4 weeks. ORs for EASI-90 (OR 3.3; 95% CI 1.0–11.3), IGA 0/1 (OR 3.3; 95% CI 0.7–15.1), and PP-NRS (OR 8.8; 95% CI 0.9–84.8) numerically favored dupilumab. Conclusions Placebo-adjusted Bucher ITC analyses showed that the likelihood of achieving efficacy outcomes at 16 weeks and maintaining efficacy outcomes at 52 weeks was higher for dupilumab versus lebrikizumab recipients. Graphical Abstracthttps://doi.org/10.1007/s13555-025-01479-yAtopic dermatitisBucher indirect treatment comparisonDupilumabIndirect treatment comparisonLebrikizumab |
| spellingShingle | Sonja Ständer Andreas Pinter Firas G. Hougeir Patricia Guyot Yingxin Xu Amy H. Praestgaard Nick Freemantle Ana B. Rossi Gaëlle Bégo-Le-Bagousse Zhixiao Wang Kerry Noonan Mike Bastian Dupilumab versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison Dermatology and Therapy Atopic dermatitis Bucher indirect treatment comparison Dupilumab Indirect treatment comparison Lebrikizumab |
| title | Dupilumab versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison |
| title_full | Dupilumab versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison |
| title_fullStr | Dupilumab versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison |
| title_full_unstemmed | Dupilumab versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison |
| title_short | Dupilumab versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison |
| title_sort | dupilumab versus lebrikizumab demonstrates greater likelihood of achieving and maintaining improvements in efficacy outcomes using a placebo adjusted indirect treatment comparison |
| topic | Atopic dermatitis Bucher indirect treatment comparison Dupilumab Indirect treatment comparison Lebrikizumab |
| url | https://doi.org/10.1007/s13555-025-01479-y |
| work_keys_str_mv | AT sonjastander dupilumabversuslebrikizumabdemonstratesgreaterlikelihoodofachievingandmaintainingimprovementsinefficacyoutcomesusingaplaceboadjustedindirecttreatmentcomparison AT andreaspinter dupilumabversuslebrikizumabdemonstratesgreaterlikelihoodofachievingandmaintainingimprovementsinefficacyoutcomesusingaplaceboadjustedindirecttreatmentcomparison AT firasghougeir dupilumabversuslebrikizumabdemonstratesgreaterlikelihoodofachievingandmaintainingimprovementsinefficacyoutcomesusingaplaceboadjustedindirecttreatmentcomparison AT patriciaguyot dupilumabversuslebrikizumabdemonstratesgreaterlikelihoodofachievingandmaintainingimprovementsinefficacyoutcomesusingaplaceboadjustedindirecttreatmentcomparison AT yingxinxu dupilumabversuslebrikizumabdemonstratesgreaterlikelihoodofachievingandmaintainingimprovementsinefficacyoutcomesusingaplaceboadjustedindirecttreatmentcomparison AT amyhpraestgaard dupilumabversuslebrikizumabdemonstratesgreaterlikelihoodofachievingandmaintainingimprovementsinefficacyoutcomesusingaplaceboadjustedindirecttreatmentcomparison AT nickfreemantle dupilumabversuslebrikizumabdemonstratesgreaterlikelihoodofachievingandmaintainingimprovementsinefficacyoutcomesusingaplaceboadjustedindirecttreatmentcomparison AT anabrossi dupilumabversuslebrikizumabdemonstratesgreaterlikelihoodofachievingandmaintainingimprovementsinefficacyoutcomesusingaplaceboadjustedindirecttreatmentcomparison AT gaellebegolebagousse dupilumabversuslebrikizumabdemonstratesgreaterlikelihoodofachievingandmaintainingimprovementsinefficacyoutcomesusingaplaceboadjustedindirecttreatmentcomparison AT zhixiaowang dupilumabversuslebrikizumabdemonstratesgreaterlikelihoodofachievingandmaintainingimprovementsinefficacyoutcomesusingaplaceboadjustedindirecttreatmentcomparison AT kerrynoonan dupilumabversuslebrikizumabdemonstratesgreaterlikelihoodofachievingandmaintainingimprovementsinefficacyoutcomesusingaplaceboadjustedindirecttreatmentcomparison AT mikebastian dupilumabversuslebrikizumabdemonstratesgreaterlikelihoodofachievingandmaintainingimprovementsinefficacyoutcomesusingaplaceboadjustedindirecttreatmentcomparison |